Johnson & Johnson (NYSE:JNJ) Shares Sold by Amalgamated Bank

Amalgamated Bank cut its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 9.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 606,733 shares of the company’s stock after selling 59,935 shares during the period. Johnson & Johnson makes up 0.8% of Amalgamated Bank’s investment portfolio, making the stock its 15th biggest holding. Amalgamated Bank’s holdings in Johnson & Johnson were worth $94,499,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Hibernia Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $27,000. FNY Investment Advisers LLC acquired a new stake in Johnson & Johnson during the 3rd quarter valued at $37,000. Tower View Wealth Management LLC grew its holdings in Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 165 shares during the last quarter. Creative Capital Management Investments LLC grew its holdings in Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after buying an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC acquired a new stake in Johnson & Johnson during the 2nd quarter valued at $48,000. Institutional investors and hedge funds own 68.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $167.00 to $180.00 in a report on Friday, December 1st. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Tuesday, February 6th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, January 24th. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $176.14.

Get Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Trading Up 0.2 %

NYSE:JNJ opened at $156.76 on Monday. The business’s 50-day moving average is $158.20 and its two-hundred day moving average is $158.73. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.21 and a quick ratio of 0.96. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $175.97. The firm has a market capitalization of $377.37 billion, a PE ratio of 11.35, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same period last year, the company posted $2.35 earnings per share. The firm’s revenue was down 9.7% compared to the same quarter last year. Research analysts predict that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be given a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 3.04%. The ex-dividend date of this dividend is Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 34.47%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.